190 related articles for article (PubMed ID: 32815181)
21. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
22. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
23. Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data.
Gröner A
Biotechnol Prog; 2024; 40(1):e3398. PubMed ID: 37985214
[TBL] [Abstract][Full Text] [Related]
24. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
25. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.
Farcet MR; Lackner C; Antoine G; Rabel PO; Wieser A; Flicker A; Unger U; Modrof J; Kreil TR
Transfusion; 2016 Feb; 56(2):383-91. PubMed ID: 26399175
[TBL] [Abstract][Full Text] [Related]
27. Blood protein purification and simultaneous removal of nonenveloped viruses using tangential-flow preparative electrophoresis.
Evtushenko M; Wang K; Stokes HW; Nair H
Electrophoresis; 2005 Jan; 26(1):28-34. PubMed ID: 15624167
[TBL] [Abstract][Full Text] [Related]
28. Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles.
Adan-Kubo J; Tsujikawa M; Takahashi K; Hongo-Hirasaki T; Sakai K
Biotechnol Prog; 2019 Nov; 35(6):e2875. PubMed ID: 31228338
[TBL] [Abstract][Full Text] [Related]
29. Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro feasibility assessment.
Chou ML; Lin LT; Devos D; Burnouf T
Transfusion; 2015 Oct; 55(10):2433-44. PubMed ID: 25988671
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic characterization of cell culture-derived hepatitis E virus subjected to different chemical treatments: Application in virus removal via nanofiltration.
Ideno S; Inoue T; Takahashi K; Urayama T; Maeno H; Takeuchi K; Sakai K
J Virol Methods; 2021 Oct; 296():114244. PubMed ID: 34302862
[TBL] [Abstract][Full Text] [Related]
31. Removal of parvovirus B19 from hemoglobin solution by nanofiltration.
Abe H; Sugawara H; Hirayama J; Ihara H; Kato T; Ikeda H; Ikebuchi K
Artif Cells Blood Substit Immobil Biotechnol; 2000 Sep; 28(5):375-83. PubMed ID: 11009110
[TBL] [Abstract][Full Text] [Related]
32. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of viral removal by nanofiltration using real-time quantitative polymerase chain reaction.
Zhao X; Bailey MR; Emery WR; Lambooy PK; Chen D
Biotechnol Appl Biochem; 2007 Jun; 47(Pt 2):97-104. PubMed ID: 17233631
[TBL] [Abstract][Full Text] [Related]
34. Choice of parvovirus model for validation studies influences the interpretation of the effectiveness of a virus filtration step.
Nowak T; Popp B; Roth NJ
Biologicals; 2019 Jul; 60():85-92. PubMed ID: 31105022
[TBL] [Abstract][Full Text] [Related]
35. [Viral safety of biologicals].
Barin F
Ann Pharm Fr; 2008 Jun; 66(3):129-39. PubMed ID: 18706341
[TBL] [Abstract][Full Text] [Related]
36. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step.
Koenderman AH; ter Hart HG; Prins-de Nijs IM; Bloem J; Stoffers S; Kempers A; Derksen GJ; Al B; Dekker L; Over J
Biologicals; 2012 Nov; 40(6):473-81. PubMed ID: 22901944
[TBL] [Abstract][Full Text] [Related]
37. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
38. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates.
Burnouf-Radosevich M; Appourchaux P; Huart JJ; Burnouf T
Vox Sang; 1994; 67(2):132-8. PubMed ID: 7801601
[TBL] [Abstract][Full Text] [Related]
39. Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb).
Azari M; Boose JA; Burhop KE; Camacho T; Catarello J; Darling A; Ebeling AA; Estep TN; Pearson L; Guzder S; Herren J; Ogle K; Paine J; Rohn K; Sarajari R; Sun CS; Zhang L
Biologicals; 2000 Jun; 28(2):81-94. PubMed ID: 10885615
[TBL] [Abstract][Full Text] [Related]
40. Virus Filtration and Flow Variation: An Approach To Evaluate Any Potential Impact on Virus Retention.
Wieser A; Berting A; Medek C; Poelsler G; Kreil TR;
PDA J Pharm Sci Technol; 2016; 70(4):325-31. PubMed ID: 27020648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
